Aviragen Therapeutics - Company & Market Research Reports

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The company has four Phase 2 clinical programs: vapendavir, vapendavir, BTA585 and BTA074. Aviragen changed its name from Biota in 2016 to reflect its transition from a drug discovery company to one focused on late-stage products treating viral diseases. Founded in 1969, Aviragen Therapeutics is headquartered in Alpharetta, Georgia.

From
From
From
From
From
Warts Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

Warts Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • 155 Pages
From
From
Rhinovirus Infection - Pipeline Insight, 2018 - Product Thumbnail Image

Rhinovirus Infection - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Condyloma - Pipeline Insight, 2018 - Product Thumbnail Image

Condyloma - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
From
From
From
From
From
Aviragen Therapeutics Inc - Product Thumbnail Image

Aviragen Therapeutics Inc

  • Company Profile
  • 51 Pages
Loading Indicator
adroll